NASH

Metabolic·MeSH: Liver Cirrhosis

Prevalence

5000.0 / 100K

Incidence

500.0 / 100K/yr

30 drugs in development·23 companies·4 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
orbera	Apollo Endosurgery, Inc. (APEN)

Phase 3(8)

Drug	Company
100 mg resmetirom	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
cenicriviroc	Allergan plc (AGN)
Efruxifermin	Keros Therapeutics, Inc. (KROS)
efruxifermin (EFX)	Akero Therapeutics, Inc. (AKRO)
iva337	Inventiva S.A. (IVEVF)
iva337	Inventiva S.A. (IVA)
Pegozafermin	89bio, Inc. (ETNB)
Resmetirom	MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Phase 2(13)

Drug	Company
axa1125	Axcella Health Inc. (AXLA)
BIO89-100	89bio, Inc. (ETNB)
efruxifermin	Akero Therapeutics, Inc. (AKRO)
EFX	Akero Therapeutics, Inc. (AKRO)
hm15211	ANI PHARMACEUTICALS INC (ANIP)
mgl-3196	MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MLR-1023	Adhera Therapeutics, Inc. (ATRX)
ngm282	NGM BIOPHARMACEUTICALS INC (NGM)
PLN-1474	PLIANT THERAPEUTICS, INC. (PLRX)
Rencofilstat (formerly CRV431; CPI-431-32)	Hepion Pharmaceuticals, Inc. (CTRVP)
rencofilstat (formerly CRV431)	Hepion Pharmaceuticals, Inc. (CTRVP)
seladelpar	CymaBay Therapeutics, Inc. (CBAY)
VK2809	Viking Therapeutics, Inc. (VKTX)

Phase 1(3)

Drug	Company
aramchol free acid	Galmed Pharmaceuticals Ltd. (GLMD)
cb4211	COHBAR, INC. (COBU)
miricorilant	CORCEPT THERAPEUTICS INC (CORT)

Preclinical(3)

Drug	Company
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)
hydrogel candidates for nafld/nash	GELESIS HOLDINGS, INC. (GLS)
jkb-122	Biostax Corp. (BTAX)

Phase 1/Phase 2(2)

Drug	Company
ft-4101	Forma Therapeutics Holdings, Inc. (FMTX)
ft-8225	Forma Therapeutics Holdings, Inc. (FMTX)

BioSniper tracks 30 drugs in development for NASH across 23 companies.

There are 4 clinical trials targeting NASH tracked by BioSniper.

The estimated prevalence of NASH is approximately 5000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.